| Dr David James Guist Dillon, MD, PHD | |
|
2315 Stockton Blvd, Sacramento, CA 95817-2201 | |
| (916) 734-8568 | |
| Not Available |
| Full Name | Dr David James Guist Dillon |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 2315 Stockton Blvd, Sacramento, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043741028 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A159976 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Davis Medical Center | Sacramento, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The Univ Of Ca | 3375456619 | 1346 |
News Archive
The future of basic and translational research in health care depends on the ability of large, complex health science centers to educate, discover new answers to extremely complicated problems and operate for the public good.
Longitudinal monitoring of 30 tests for marker candidates in early Parkinson's disease has found that just 10 show significant changes commensurate with disease progression.
Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
› Verified 8 days ago
| Entity Name | Regents Of The Univ Of Ca |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013906973 PECOS PAC ID: 3375456619 Enrollment ID: O20031111000892 |
News Archive
The future of basic and translational research in health care depends on the ability of large, complex health science centers to educate, discover new answers to extremely complicated problems and operate for the public good.
Longitudinal monitoring of 30 tests for marker candidates in early Parkinson's disease has found that just 10 show significant changes commensurate with disease progression.
Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
› Verified 8 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366417420 PECOS PAC ID: 5496668410 Enrollment ID: O20031112000551 |
News Archive
The future of basic and translational research in health care depends on the ability of large, complex health science centers to educate, discover new answers to extremely complicated problems and operate for the public good.
Longitudinal monitoring of 30 tests for marker candidates in early Parkinson's disease has found that just 10 show significant changes commensurate with disease progression.
Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
› Verified 8 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
The future of basic and translational research in health care depends on the ability of large, complex health science centers to educate, discover new answers to extremely complicated problems and operate for the public good.
Longitudinal monitoring of 30 tests for marker candidates in early Parkinson's disease has found that just 10 show significant changes commensurate with disease progression.
Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
› Verified 8 days ago
| Entity Name | San Francisco Emergency Medical |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134110661 PECOS PAC ID: 5698662518 Enrollment ID: O20040303001130 |
News Archive
The future of basic and translational research in health care depends on the ability of large, complex health science centers to educate, discover new answers to extremely complicated problems and operate for the public good.
Longitudinal monitoring of 30 tests for marker candidates in early Parkinson's disease has found that just 10 show significant changes commensurate with disease progression.
Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
› Verified 8 days ago
| Entity Name | Ucsf Medical Group Business Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
The future of basic and translational research in health care depends on the ability of large, complex health science centers to educate, discover new answers to extremely complicated problems and operate for the public good.
Longitudinal monitoring of 30 tests for marker candidates in early Parkinson's disease has found that just 10 show significant changes commensurate with disease progression.
Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David James Guist Dillon, MD, PHD 2315 Stockton Blvd, Sacramento, CA 95817-2201 Ph: (916) 734-8568 | Dr David James Guist Dillon, MD, PHD 2315 Stockton Blvd, Sacramento, CA 95817-2201 Ph: (916) 734-8568 |
News Archive
The future of basic and translational research in health care depends on the ability of large, complex health science centers to educate, discover new answers to extremely complicated problems and operate for the public good.
Longitudinal monitoring of 30 tests for marker candidates in early Parkinson's disease has found that just 10 show significant changes commensurate with disease progression.
Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
› Verified 8 days ago
Elizabeth Johnson, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2315 Stockton Blvd, Sacramento, CA 95817 Phone: 916-734-8570 | |
Timothy Sturgill, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7500 Hospital Dr, Sacramento, CA 95823 Phone: 330-493-4443 | |
Jon Haynes, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2315 Stockton Blvd, Sacramento, CA 95817 Phone: 916-734-8570 Fax: 916-734-7950 | |
Mark Portman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2315 Stockton Blvd., Sacramento, CA 95817 Phone: 916-734-8570 Fax: 916-734-7950 | |
Juliette Gerardo, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2315 Stockton Blvd, Sacramento, CA 95817 Phone: 916-734-2011 | |
Dr. John Ray Richards, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2315 Stockton Blvd, Pssb 2100 Emergency Medicine, Sacramento, CA 95817 Phone: 916-734-1537 Fax: 916-734-7950 | |
Kerilee Wenker, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2801 L St, Sacramento, CA 95816 Phone: 916-454-2222 |